Prognostic markers in pancreatic ductal adenocarcinomas

Cancer Biology and Therapy

Volumn 7, Issue 9, 2008, Pages 1360-1361

  Hezel, Aram F ^a   Bardeesy, Nabeel ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cyclophosphamide; Everolimus; Gastric cancer; HIF 1 ; Metronomic chemotherapy; mTOR

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; JANUS KINASE; PROTEIN KINASE PIM 1; STAT PROTEIN; PIM1 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; NONHUMAN; NOTE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREATITIS; PROGNOSIS; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-PIM-1; TUMOR MARKERS, BIOLOGICAL;

EID: 58149151414     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.9.6955     Document Type: Note

References (8)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363:1049-57.
2. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008; 12:701-6.
3. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70:255-64.
4. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41:2213-36.
5. Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, Streit S, Michalski CW, Friess H, Kleeff J. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2008; 7:XXX.
6. Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005; 37:726-30.
7. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115:2618-24.
8. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24:6104-15.